Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 11575 | 906 | 38.3 | 92% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CHEK2 | Author keyword | 75 | 68% | 7% | 66 |
| 2 | PALB2 | Author keyword | 64 | 75% | 5% | 47 |
| 3 | SERV CIRUGIA GEN ESPECIALIDADES | Address | 45 | 83% | 3% | 25 |
| 4 | CANC GENET EPIDEMIOL | Address | 37 | 38% | 9% | 79 |
| 5 | UNIT MOL BASES GENET RISK GENET TESTING | Address | 33 | 53% | 5% | 44 |
| 6 | CANC GENET TUMOR BIOL | Address | 31 | 76% | 2% | 22 |
| 7 | MED BIOMETR EPIDEMIOL | Address | 26 | 50% | 4% | 38 |
| 8 | ONTARIO CANC GENET NETWORK | Address | 21 | 48% | 3% | 31 |
| 9 | TAIWAN BIOBANK | Address | 18 | 67% | 2% | 16 |
| 10 | CHEK2 GENE | Author keyword | 15 | 82% | 1% | 9 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CHEK2 | 75 | 68% | 7% | 66 | Search CHEK2 | Search CHEK2 |
| 2 | PALB2 | 64 | 75% | 5% | 47 | Search PALB2 | Search PALB2 |
| 3 | CHEK2 GENE | 15 | 82% | 1% | 9 | Search CHEK2+GENE | Search CHEK2+GENE |
| 4 | CHEK2 1100DELC | 11 | 100% | 1% | 6 | Search CHEK2+1100DELC | Search CHEK2+1100DELC |
| 5 | TOX3 | 11 | 100% | 1% | 6 | Search TOX3 | Search TOX3 |
| 6 | RAD51C | 10 | 48% | 2% | 15 | Search RAD51C | Search RAD51C |
| 7 | CHK2 GENE | 8 | 100% | 1% | 5 | Search CHK2+GENE | Search CHK2+GENE |
| 8 | TNRC9 | 8 | 100% | 1% | 5 | Search TNRC9 | Search TNRC9 |
| 9 | BRIP1 | 7 | 50% | 1% | 10 | Search BRIP1 | Search BRIP1 |
| 10 | 2Q35 | 4 | 75% | 0% | 3 | Search 2Q35 | Search 2Q35 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CONFER SUSCEPTIBILITY | 129 | 57% | 17% | 154 |
| 2 | CHEK2 ASTERISK 1100DELC | 69 | 63% | 8% | 70 |
| 3 | CHEK2 ASTERISK 1100DELC VARIANT | 45 | 94% | 2% | 16 |
| 4 | 14Q241 RAD51L1 | 34 | 93% | 1% | 13 |
| 5 | 1100DELC MUTATION | 29 | 88% | 2% | 14 |
| 6 | CHEK2 | 27 | 55% | 4% | 34 |
| 7 | BRCA2 INTERACTING PROTEIN | 20 | 62% | 2% | 21 |
| 8 | 6Q251 | 20 | 100% | 1% | 9 |
| 9 | CHK2 | 19 | 29% | 6% | 56 |
| 10 | PALB2 | 16 | 41% | 3% | 30 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Genetic Susceptibility to Triple-Negative Breast Cancer | 2013 | 27 | 45 | 56% |
| The CHEK2 gene and inherited breast cancer susceptibility | 2006 | 79 | 71 | 73% |
| Breast cancer genome-wide association studies: there is strength in numbers | 2012 | 25 | 54 | 44% |
| Testing for CHEK2 in the cancer genetics clinic: ready for prime time? | 2010 | 24 | 54 | 81% |
| Common breast cancer risk variants in the post-COGS era: a comprehensive review | 2013 | 7 | 101 | 73% |
| Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment | 2015 | 2 | 35 | 29% |
| PALB2/FANCN: Recombining Cancer and Fanconi Anemia | 2010 | 48 | 44 | 55% |
| Inherited Genetic Susceptibility to Breast Cancer The Beginning of the End or the End of the Beginning? | 2013 | 13 | 96 | 41% |
| Genetics of breast cancer: a topic in evolution | 2015 | 2 | 70 | 21% |
| Genetic susceptibility to breast cancer | 2010 | 96 | 146 | 24% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | SERV CIRUGIA GEN ESPECIALIDADES | 45 | 83% | 2.8% | 25 |
| 2 | CANC GENET EPIDEMIOL | 37 | 38% | 8.7% | 79 |
| 3 | UNIT MOL BASES GENET RISK GENET TESTING | 33 | 53% | 4.9% | 44 |
| 4 | CANC GENET TUMOR BIOL | 31 | 76% | 2.4% | 22 |
| 5 | MED BIOMETR EPIDEMIOL | 26 | 50% | 4.2% | 38 |
| 6 | ONTARIO CANC GENET NETWORK | 21 | 48% | 3.4% | 31 |
| 7 | TAIWAN BIOBANK | 18 | 67% | 1.8% | 16 |
| 8 | CRUK YCR SHEFFIELD CANC | 15 | 77% | 1.1% | 10 |
| 9 | HUMAN GENOTYPING CEGEN UNIT | 15 | 73% | 1.2% | 11 |
| 10 | FAMILY CANC CLIN | 14 | 26% | 5.2% | 47 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000187490 | BRCA1//BRCA2//HEREDITARY BREAST CANCER |
| 2 | 0.0000158654 | RNASEL//HEREDITARY PROSTATE CANCER//8Q24 |
| 3 | 0.0000141788 | LI FRAUMENI SYNDROME//LI FRAUMENI//GERMLINE P53 MUTATION |
| 4 | 0.0000109604 | CASP10//CASP8//CASPASE 10 |
| 5 | 0.0000096830 | ARLTS1//HERITABLE CANCER//FAMILIAL RISK |
| 6 | 0.0000077002 | CHK1//RAD9//CLASPIN |
| 7 | 0.0000072012 | FANCONI ANEMIA//FANCONI ANAEMIA//FANCD2 |
| 8 | 0.0000068347 | OLAPARIB//SYNTHETIC LETHALITY//PARP INHIBITOR |
| 9 | 0.0000067797 | RARE VARIANTS//GENETIC EPIDEMIOLOGY//RARE VARIANT ANALYSIS |
| 10 | 0.0000061544 | BRMS1//BREAST CANCER METASTASIS SUPPRESSOR 1//FDN CANC METASTASIS |